June 26, 2019 EyeGate Announces First Patient Enrolled in PRK Pivotal Study
(World News Science)

WALTHAM, Mass., June 26, 2019 (ACCESSWIRE) - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (`EyeGate` or `the Company`) announced today it has enrolled the first patient in its corneal wound repair pivotal study in patients having undergone photorefractive keratectomy (`PRK`) surgery. Barbara Wirostko MD, Chief Medical Officer of EyeGate, said, `There is a significant need for an effective and accessible Hyaluronic Acid (`HA`) eyedrop formulation in the U.S. that can help re-epithelialize corneal defects due to surgery, injuries, and diseases. We believe our OGB platform would be the first to address that unmet need. We are extremely pleased with the efficiency of our team and sites in...